LEXX (lexariabioscience.com) Future Price to Earnings

The patented DehydraTECH system significantly enhances the bioavailability of substances, which is reflected in the forward P/E dynamics of Lexaria Bioscience (LEXX). The value of 0.00 represents the latest reading of this metric. Share prices are supported by the success of nicotine delivery trials and royalties. The business is currently seeking a major strategic partner to license its developments without being acquired by another corporation.

Lexaria Bioscience - LEXX Market Cap to Future Earnings Ratio (period 07/04/2022 - 11/10/2026)

Summary analytical data breakdowns for Lexaria (LEXX)

- current price and projected stock value:

Stock Quotes Lexaria Bioscience|LEXX - Fair Value Consensus

- business market valuation indicators:

Market Value Lexaria Bioscience Corp|LEXX - Total Enterprise Value

- balance sheet equity data:

Accounting Value per Share Lexaria Bioscience|LEXX - Total Net Assets|Market Capitalization to Book Value Ratio lexariabioscience.com|LEXX - Aggregate Asset Value

- debt level and financial liquidity data:

Total Debt to Capital Lexaria Bioscience|LEXX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Lexaria Bioscience|LEXX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Lexaria Bioscience Corp|LEXX - Company Long-Term Debt|Company Short-Term Debts Lexaria Bioscience|Quick Liquidity Indicator lexariabioscience.com

- financial results and valuation multiples details:

LEXX - Company Profit|Projected Future Earnings Lexaria Bioscience|LEXX - P/E Multiple|Future Price to Earnings Lexaria Bioscience|LEXX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Lexaria Bioscience Corp|LEXX - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Lexaria Bioscience|LEXX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months lexariabioscience.com|LEXX - Earnings per share increase in current year|Earnings growth forecast for next year Lexaria Bioscience

Fundamental valuation:LEXX Lexaria Bioscience Corp.

The investment appeal of Lexaria Bioscience (LEXX) is based on the monetization of DehydraTECH patents through licensing royalties, which ensures high margins in the absence of capital expenditures. The ratio of current market value to expected earnings, reflected via the company's forward P/E metric, allows for an assessment of the business valuation's fairness relative to future cash flows, confirming the fundamental stability of the intellectual property model.

Competing companies